文章：

含蒽环类药物的一线化疗方案在外周T细胞淋巴瘤中的作用

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas

原文发布日期：2014-05-30

DOI: 10.1038/bcj.2014.34

类型: Original Article

开放获取: 是

英文摘要：

Peripheral T-cell lymphomas (PTCLs) are a heterogenous group of aggressive non-Hodgkin’s lymphomas that are incurable in the majority of patients with current therapies. Outcomes associated with anthracycline-based therapies are suboptimal, but remain the standard of care for most patients, even though the benefits of this approach remain uncertain. This study retrospectively examined outcomes in a cohort of North American PTCL patients treated with both anthracycline- and nonanthracycline-containing regimens. The incorporation of anthracycline-containing regimens was associated with improved progression-free survival (PFS) and overall survival (OS). Patients treated with nonanthracycline-containing regimens were more likely to have high-risk features and were less likely to undergo high-dose therapy and stem cell transplantation. However, anthracycline use remained an independent predictor of improved PFS and OS when adjusting for these confounding variables. Anthracycline-based regimens and consolidation with high-dose therapy and autologous stem cell transplantation in appropriately selected patients remains a viable option for patients unable to participate in a clinical trial. Long-term disease-free survival is not optimal, highlighting the need for an improved understanding of disease pathogenesis, and the development of novel therapeutic strategies.

摘要翻译： 

外周T细胞淋巴瘤（PTCL）是一组异质性的侵袭性非霍奇金淋巴瘤，对于大多数患者而言，现有治疗方案难以实现疾病根治。基于蒽环类药物的治疗方案虽效果欠佳，但仍是多数患者的标准疗法，尽管该方法的疗效仍不明确。本研究回顾性分析了北美地区接受含蒽环类与不含蒽环类方案治疗的PTCL患者队列结果。采用含蒽环类方案治疗与无进展生存期（PFS）和总生存期（OS）的改善相关。接受非蒽环类方案治疗的患者更多呈现高危特征，且接受高剂量疗法及干细胞移植的可能性较低。但经混杂因素校正后，蒽环类药物的使用仍是改善PFS和OS的独立预测因子。对于无法参与临床试验的患者，基于蒽环类药物的治疗方案联合高剂量疗法及自体干细胞移植巩固治疗，仍是经合适筛选患者的可行选择。长期无病生存率仍不理想，这凸显了深化对疾病发病机制认知及开发新型治疗策略的必要性。

原文链接：

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas